The effect of exemestane on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

The effect of exemestane on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer - The effect of exemestane on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020499

Enrollment

Registered

2016-01-08

Start date

2015-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Primary breast cancer in stage 0 to IIIC Treatment with exemestane Postmenopausal E2 <30pg/ml Written informed consent is obtained

Exclusion criteria

Exclusion criteria: Patients already treated as osteoporosis

Design outcomes

Primary

Measure	Time frame
BMD change from baseline to 5 years at the lumbar spine and femoral neck	—

Secondary

Measure	Time frame
BMD change from baseline to 6, 12, 24, 36, 48, and 72 months at the lumbar spine and femoral neck Bone fracture rate during 5 years	—

Countries

Japan

Contacts

Public ContactAkira Hirano

Medical Center East, Tokyo Women's Medical University Department of Breast Surgery

ahirasu@dnh.twmu.ac.jp03-3810-1111

Outcome results